However, an increasing number of studies has demonstrated that changes in the tumor immune microenvironment during checkpoint blockade therapy, such as activation of PD‐1‐expressing Treg cells and CD8+ T cell exhaustion, could trigger the acceleration of tumor growth. This evidence concerns the gene CD8A and neoplasm.